Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.
暂无分享,去创建一个
Ivan Jambor | Matthias Nees | Pekka Taimen | Otto Ettala | Ileana Montoya Perez | Kim Pettersson | Peter J Boström | P. Taimen | P. Boström | H. Aronen | I. Jambor | M. Nees | K. Pettersson | M. Kallajoki | S. Alinezhad | Saeid Alinezhad | Riina-Minna Väänänen | Terhi Tallgrén | I. M. Perez | O. Ettala | Markku Kallajoki | Hannu Aronen | Esa Kähkönen | Kari Syvänen | K. Syvänen | T. Tallgrén | Esa Kähkönen | R. Väänänen
[1] Gilles Louppe,et al. Independent consultant , 2013 .
[2] L. Marks,et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. , 2006, Clinical chemistry.
[3] H. Merisaari,et al. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy , 2015, Journal of magnetic resonance imaging : JMRI.
[4] K. Pettersson,et al. Quantitative real-time RT-PCR assay for PCA3. , 2008, Clinical biochemistry.
[5] J. Schalken,et al. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis , 2013, The Prostate.
[6] A. Ylikoski,et al. Time-resolved fluorometry in end-point and real-time PCR quantification of nucleic acids. , 2000, Luminescence : the journal of biological and chemical luminescence.
[7] G. Jenster,et al. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer , 2013, International journal of cancer.
[8] Thomas Hambrock,et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. , 2010, The Journal of urology.
[9] M. Cooperberg,et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Leys,et al. Optimization of preservation and storage time of sponge tissues to obtain quality mRNA for next‐generation sequencing , 2012, Molecular ecology resources.
[11] Matthias Nees,et al. Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies , 2016, PloS one.
[12] B. Trock,et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high‐risk cohort of men with negative initial prostate biopsies , 2012, BJU international.
[13] P. Febbo,et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.
[14] Tapio Salakoski,et al. An experimental comparison of cross-validation techniques for estimating the area under the ROC curve , 2011, Comput. Stat. Data Anal..
[15] M. Karp,et al. High-performance real-time quantitative RT-PCR using lanthanide probes and a dual-temperature hybridization assay. , 2002, Analytical chemistry.
[16] L. Pusztai,et al. Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. , 2011, Journal of the National Cancer Institute.
[17] H. Lilja,et al. Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens. , 2013, Clinical biochemistry.
[18] O. Kallioniemi,et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG‐positive prostate cancer , 2008, International journal of cancer.
[19] Andrew J Vickers,et al. Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens. , 2014, Urology.
[20] Pekka Taimen,et al. Global expression of AMACR transcripts predicts risk for prostate cancer – a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate , 2016, BMC Urology.
[21] Zhaohui S. Qin,et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.
[22] O. Kallioniemi,et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.
[23] C. Roehrborn,et al. Using biopsy to detect prostate cancer. , 2008, Reviews in urology.
[24] David L Rimm,et al. Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer , 2015, Clinical Cancer Research.
[25] J. Oxley,et al. Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study , 2011, British Journal of Cancer.
[26] H. Lehrach,et al. ERG Induces Epigenetic Activation of Tudor Domain-Containing Protein 1 (TDRD1) in ERG Rearrangement-Positive Prostate Cancer , 2013, PloS one.
[27] Anonymous Author. Robust Reductions from Ranking to Classification , 2006 .
[28] Vijayalakshmi Ananthanarayanan,et al. Evidence for field cancerization of the prostate , 2009, The Prostate.
[29] Tania Nolan,et al. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. , 2004, Journal of biomolecular techniques : JBT.
[30] William J Catalona,et al. Serial biopsy results in prostate cancer screening study. , 2002, The Journal of urology.